Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Role of the Aging Bladder in Lower Urinary Tract Symptoms: Pathophysiology and Therapeutic Implications in Patients with Benign Prostatic Hyperplasia.

Medicina (Kaunas, Lithuania)·2026

Same author

Erectile Function Decline in Men with Chronic Kidney Disease: A Three-Year Case-Control Study Comparing Haemodialysis, Non-Dialysis CKD and Community Controls.

Journal of clinical medicine·2026

Same author

Erectile Dysfunction in Chronic Kidney Disease and Hemodialysis Patients: A State-of-the-Art Review.

Cureus·2025

Same author

Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette-Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece.

Current oncology (Toronto, Ont.)·2025

Same author

Grading Challenges and Prognostic Insights in Chromophobe Renal Cell Carcinoma: A Retrospective Study of 72 Patients.

Medicina (Kaunas, Lithuania)·2024

Same author

Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study.

Investigative and clinical urology·2023

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Looking to the future for erectile dysfunction therapies.

Konstantinos Hatzimouratidis¹, Dimitrios G Hatzichristou

¹Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, Thessaloniki, Greece.

|January 17, 2008

Summary

Erectile dysfunction (ED) treatments have advanced significantly, with phosphodiesterase type 5 (PDE5) inhibitors as a primary option. Future treatments aim for personalized medicine with diverse mechanisms of action.

Related Experiment Videos

Last Updated: Jul 8, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

Urology
Pharmacology
Sexual Medicine

Background:

Erectile dysfunction (ED) treatment has seen major advancements over the past two decades.
Current therapies, primarily phosphodiesterase type 5 (PDE5) inhibitors, offer high efficacy and safety.
A comprehensive review of ED treatment modalities is essential.

Purpose of the Study:

To evaluate available data on current and emerging treatment options for erectile dysfunction.
To highlight the role of PDE5 inhibitors and discuss new drug candidates.
To explore future therapeutic avenues, including gene therapy and tissue engineering.

Main Methods:

A MEDLINE search was conducted to gather data on ED treatment modalities.
Analysis of pharmacokinetic profiles and safety data for existing and novel drugs.
Review of ongoing research in gene therapy and tissue engineering for ED.

Main Results:

Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are the current first-line treatment for ED.
New PDE5 inhibitors (e.g., avanafil, udenafil) are in development, requiring improved pharmacokinetic profiles.
Emerging treatments include receptor agonists, guanylate cyclase activators, rho-kinase inhibitors, and regenerative medicine approaches.

Conclusions:

No single ideal treatment for ED currently exists, necessitating patient awareness of all options.
Future advancements in drug development and personalized medicine will enhance ED treatment efficacy and safety.
Adopting a patient-centered care model in sexual medicine is crucial for optimizing outcomes.